Behavioral science in biopharma: Convincing backers and physicians to support new drugs requires more than education

Novel therapies, often with expensive price tags and finite patient populations, require strategic new positioning if they are to have maximum positive impact. Here, Alpharmaxim’s William Hind explains the science of behavioral change and how, applied as an integral part of medical communications, it could help deliver important new drugs to those who need them.